Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMalignant neoplasms of lymphoid, hematopoietic and related tissueICD-10-CM c90-multiple-myeloma-and-plasma-cell-neoplasms
    Ask Trek AI about this page

    ICD-10-CM Code For Multiple Myeloma And Malignant Plasma Cell Neoplasms: Group Overview

    The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) code group C90 includes malignant plasma cell neoplasms such as multiple myeloma and related plasma cell dyscrasias that primarily involve the bone marrow and can produce systemic complications. These ICD-10-CM diagnosis codes are used to document clinical situations including active malignancy management, complications such as renal failure or bone lesions, and longitudinal monitoring of disease status. Accurate coding within the ICD-10-CM C90 group supports proper claim adjudication, complete clinical documentation, and appropriate reimbursement.

    Customize your policy alerts

    Sign up for ICD-10-CM Code For Multiple Myeloma And Malignant Plasma Cell Neoplasms: Group Overview policy alerts

    Get alerted when relevant policies change without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    ICD-10-CM C90: Multiple Myeloma And Malignant Plasma Cell Neoplasms Overview

    The ICD-10-CM C90 group comprises malignant plasma cell disorders, including multiple myeloma and related neoplasms that primarily affect the bone marrow and hematopoietic system. These diagnoses target plasma cell malignancies that can cause bone lesions, anemia, renal impairment, and immunodeficiency. Accurate coding matters for appropriate clinical documentation and reimbursement because it captures disease severity, complications, and resource utilization.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    When to Use

    Use a code from this group when a clinician documents a diagnosed malignant plasma cell neoplasm such as multiple myeloma or a related plasma cell disorder. Select the specific code that reflects disease activity, anatomic complications, and any documented organ dysfunction or treatment status.

    ICD-10-CM Codes

    12 rows

    ICD-10-CM CodeDescription
    C90.00Multiple myeloma not having achieved remission
    C90.01Multiple myeloma in remission
    C90.02Multiple myeloma in relapse
    C90.10Plasma cell leukemia not having achieved remission
    C90.11Plasma cell leukemia in remission
    C90.12Plasma cell leukemia in relapse
    C90.20Extramedullary plasmacytoma not having achieved remission
    C90.21Extramedullary plasmacytoma in remission
    C90.22Extramedullary plasmacytoma in relapse
    C90.30Solitary plasmacytoma not having achieved remission
    C90.31Solitary plasmacytoma in remission
    C90.32Solitary plasmacytoma in relapse

    DRG Codes

    9 rows

    DRG CodeDescription
    820Lymphoma and Leukemia with Major O.R. Procedures with MCC
    821Lymphoma and Leukemia with Major O.R. Procedures with CC
    822Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC
    823Lymphoma and Non-Acute Leukemia with Other Procedures with MCC
    824Lymphoma and Non-Acute Leukemia with Other Procedures with CC
    825Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC
    840Lymphoma and Non-Acute Leukemia with MCC
    841Lymphoma and Non-Acute Leukemia with CC
    842Lymphoma and Non-Acute Leukemia without CC/MCC

    Typical Clinical Scenarios

    • An elderly patient with progressive fatigue, bone pain, and new anemia is evaluated in outpatient hematology. Laboratory testing shows markedly elevated serum protein with a monoclonal spike on SPEP, clonal plasma cells on bone marrow biopsy, and lytic lesions on skeletal survey; the patient is newly diagnosed with symptomatic multiple myeloma requiring staging and initiation of therapy. Typical codes: C90.00, C90.01.
    • A middle-aged patient receiving routine oncologic follow-up after initial therapy presents with rising M-protein on serial monitoring but no CRAB (hyperCalcemia, Renal failure, Anemia, Bone lesions) features; this represents persistent or relapsing disease activity without acute organ damage. A diagnosis code from this group is assigned to document active multiple myeloma status during surveillance and treatment planning. Typical codes: C90.10, C90.11.
    • A patient admitted to the hospital with acute renal failure and hypercalcemia in the setting of known plasma cell malignancy presents as an emergency complication requiring inpatient management. The hospitalization is coded to reflect the malignant plasma cell neoplasm with associated complications and acute organ dysfunction related to disease activity. Typical codes: C90.30, C90.31.

    Related Codes

    C81-HODGKIN-LYMPHOMA

    ICD-10-CM Code For Hodgkin Lymphoma: Group Overview

    C82-FOLLICULAR-LYMPHOMA

    ICD-10-CM Code For Follicular Lymphoma: Group Overview

    C83-NON-FOLLICULAR-LYMPHOMA

    ICD-10-CM Code For Non-Follicular Lymphoma: Group Overview

    C84-MATURE-T-NK-CELL-LYMPHOMAS

    ICD-10-CM Code For Mature T/NK-Cell Lymphomas: Group Overview

    C85-OTHER-SPECIFIED-AND-UNSPECIFIED-NON-HODGKIN-LYMPHOMA

    ICD-10-CM Code For Other Specified And Unspecified Types Of Non Hodgkin Lymphoma: Group Overview

    C86-OTHER-SPECIFIED-T-NK-CELL-LYMPHOMA

    ICD-10-CM Code For Other Specified Types Of T NK Cell Lymphoma: Group Overview

    C88-MALIGNANT-IMMUNOPROLIFERATIVE-DISEASES

    ICD-10-CM Code For Malignant Immunoproliferative Diseases And Certain Other B-Cell Lymphomas: Group Overview

    C91-LYMPHOID-LEUKEMIA

    ICD-10-CM Code For Lymphoid Leukemia: Group Overview

    C92-MYELOID-LEUKEMIA

    ICD-10-CM Code For Myeloid Leukemia: Group Overview

    C93-MONOCYTIC-LEUKEMIA

    ICD-10-CM Code For Monocytic Leukemia: Group Overview

    Showing 1–10 of 13

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.